Search Results
Your search for all items matches 36929 pages
Showing 1 - 50FDA Approves New Labeling of ROS1 Inhibitor in TKI-Naive Advanced NSCLC
The U.S. Food and Drug Administration (FDA) has approved updated labeling of taletrectinib (Ibtrozi), an oral, CNS-active, selective next-generation ROS1 inhibitor therapy for non–small cell lung cancer (NSCLC), reflecting a median duration of response of 49.7 months in tyrosine kinase inhibitor...
First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC
Trastuzumab deruxtecan significantly improved progression-free survival over pembrolizumab plus platinum-based chemotherapy for patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC) who were being treated in the first-line setting, according to phase III DESTINY-Lung04 ...
Zipalertinib Added to Chemotherapy Improves PFS in First-Line EGFR Exon 20+ NSCLC
The addition of zipalertinib to platinum-pemetrexed chemotherapy led to a significant improvement in progression-free survival in patients with advanced non–small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation, according to phase III findings presented at the International...
OPTIMUM Trial Reports 5-Year Outcomes With Extended Therapy in High-Risk Multiple Myeloma
The 5-year follow-up of the phase II OPTIMUM/MUKnine trial found sustained improvements in progression-free and overall survival with an intensive, risk-adapted treatment strategy for patients with newly diagnosed high-risk multiple myeloma. The findings, reported by Kaiser et al in The Lancet...
NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer
The National Comprehensive Cancer Network® (NCCN®) has released a new resource to help patients and caregivers understand how to tailor cancer care for aging populations. “The medical advances we’ve seen in cardiology and infectious disease are a huge triumph; because we are better at treating...
Zidesamtinib Demonstrates 94% Response Rate in TKI-Naive Patients With Advanced ROS1-Positive NSCLC
New results from the global phase I/II ARROS-1 trial showed clinically meaningful activity with the ROS1 selective inhibitor zidesamtinib in patients with advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI). The...
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
In the large, platform-based, independent validation study CATALINA, published by Dixon-Douglas et al in The Lancet Oncology, two artificial intelligence (AI)-derived computational tumor-infiltrating lymphocyte (cTIL) models, which were deployed without retraining or modification, provided...
Chul Kim, MD, on NSCLC With EGFR Exon 20 Insertions: First-Line Amivantamab/Chemotherapy vs Chemotherapy
Chul Kim, MD, of Georgetown Cancer Institute, reviews findings from the phase III PAPILLON study, which found that first-line amivantamab plus carboplatin/pemetrexed was associated with numerically longer overall survival compared with chemotherapy alone in patients with previously untreated...
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
This September, in honor of Prostate Cancer Awareness Month, the American Cancer Society is encouraging men to discuss their risks of prostate cancer with their doctors and the possibility of screening. The American Cancer Society noted that cases of prostate cancer have continued to increase by...
PD-L1–High Metastatic NSCLC: First-Line Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Progression-Free Survival Endpoint
Sacituzumab govitecan-hziy plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS)...
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
Relapsed small cell lung cancer (SCLC) remains a major therapeutic challenge, with limited treatment options and poor outcomes after disease progression on platinum-based chemotherapy and immunotherapy. At the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on...
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
An 8-year update of the phase III ADAURA trial showed that adjuvant osimertinib continued to demonstrate an overall survival benefit over placebo in patients with resected EGFR-mutated non–small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study ...
Izalontamab Brenitecan Active in Previously Treated EGFR-Positive NSCLC
Izalontamab brenitecan (BL-B01D1), an EGFR x HER3 bispecific antibody, demonstrated antitumor activity and a tolerable safety profile, especially at higher dose levels, in patients with previously treated EGFR-mutated metastatic non–small cell lung cancer (NSCLC). These data from a randomized...
Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC
Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, was compared with pembrolizumab as first-line treatment for patients with PD-L1–positive advanced non–small cell lung cancer (NSCLC). Data from the prespecified interim analysis of the phase III HARMONi-2 trial were presented at the...
MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC
Results from the international phase III SWOG S1827 MAVERICK trial show that brain magnetic resonance imaging (MRI) surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC)....
DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
In a post hoc analysis of data from the fourth interim analysis of the DAROL trial, the androgen receptor darolutamide was well tolerated, with no cumulative toxic effects or new safety signals among patients with nonmetastatic castration-resistant prostate cancer receiving concomitant...
New Executive Director of the Duke Cancer Institute Named
David Tuveson, MD, PhD, will join Duke Health as Executive Director of the Duke Cancer Institute, effective October 31, 2026. Dr. Tuveson is currently the Roy J. Zuckerberg Professor of Cancer Research and Director of the National Cancer Institute (NCI)-designated Cancer Center at Cold Spring...
Chad G. Rusthoven, MD, on SCLC: Brain MRI Surveillance With or Without Prophylactic Cranial Irradiation
Chad G. Rusthoven, MD, of the University of Colorado School of Medicine, presents results from the international phase III SWOG S1827 MAVERICK trial, which showed that brain MRI surveillance alone improved cognitive failure–free survival compared with MRI surveillance plus prophylactic cranial...
Roy S. Herbst, MD, PhD, on Resected EGFR-Mutated NSCLC: Long-Term Overall Survival With Osimertinib
Roy S. Herbst, MD, PhD, of Dartmouth Cancer Center, discusses 8-year overall survival data from the landmark ADAURA trial, which showed the sustained long-term benefit of adjuvant therapy with osimertinib for patients with completely resected, EGFR-mutated stage IB–IIIA non–small cell lung cancer...
Alexander Drilon, MD, on Advanced Metastatic ROS1-Positive NSCLC: Zidesamtinib in TKI-Naive Patients
Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, presents efficacy and safety data from a phase II cohort of the ARROS-1 trial, which included patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who were naive to tyrosine kinase inhibitor...
Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC
Adjuvant alectinib was associated with early improvements in health-related quality of life that were maintained over 2 years of treatment in patients with resected ALK-positive non–small cell lung cancer (NSCLC). The new analysis of the phase III ALINA trial, reported by Dziadziuszko et al in The...
Extended-Interval Dosing of Tarlatamab Found Safe, Effective in SCLC
Extended-interval dosing of intravenous tarlatamab, at 20 mg every 3 weeks or 30 mg every 4 weeks, demonstrated efficacy and safety that was consistent with the approved tarlatamab dosing regimen in patients with small cell lung cancer (SCLC), according to findings from the phase II DeLLphi-309...
Favorable Safety Profile Found for Subcutaneous Tarlatamab in ES-SCLC
Subcutaneous administration of tarlatamab was well tolerated in patients with extensive-stage small cell lung cancer (ES-SCLC) in the phase IB DeLLphi-308 trial. Investigators were able to eliminate the preplanned post-dose monitoring in the second part of the study due to the safety of the...
Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer
Early-onset colorectal cancer appears to share much of its genomic landscape with average-onset colorectal cancer, although certain molecular alterations may be enriched among younger patients, according to findings reported by Shin et al in JCO Precision Oncology. The investigators examined...
FDA Approves Topical Photodynamic Therapy for Superficial BCC
Today, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for aminolevulinic acid hydrochloride topical gel, 10% (Ameluz), in combination with photodynamic therapy (PDT) using the BF-RhodoLED lamp series, for the treatment of superficial basal cell carcinoma...
Perioperative Atezolizumab Plus Chemotherapy Improves Outcomes in Resectable Stage II–IIIB NSCLC
Patients with resectable stage IIB–IIIB non–small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone. However, these results did ...
New NCCN Survey Highlights Persistent Cancer Medication Shortages Across United States
The National Comprehensive Cancer Network® (NCCN®) has published updated data on the current impact of generic cancer medication shortages in the United States. The data come from survey responses from pharmacy directors and other clinical and administrative leadership at NCCN Member Institutions...
What Constitutes Clinical Expertise in an AI-Enabled Era?
In a keynote speech delivered recently at Cleveland Clinic's A.I. Summit for Healthcare Professionals, Peter Clardy, MD, of Google for Health, made the case that the rapid evolution currently underway in AI is unfolding as clinicians are also being asked to make decisions from an ever-expanding...
Surviving Cancer Put Me On a Career Path in Cancer Research
I was just 24 and in seemingly perfect health when I began experiencing unexplained abdominal pain so excruciating, even daily doses of pain medication failed to provide relief. I was a senior in college and had enrolled in a summer internship program at the University of California, Davis, when my ...
20th Annual Award for Leadership in Personalized Medicine
The Personalized Medicine Coalition (PMC), a nonprofit organization dedicated to advancing personalized medicine, recently announced that physician-scientist Norman E. “Ned” Sharpless, MD, has been selected as the recipient of the 20th Annual Award for Leadership in Personalized Medicine,...
Envafolimab Regimen Improves Pathologic Complete Response in MSS Locally Advanced Rectal Cancer
Adding the subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX (capecitabine and oxaliplatin) improved pathologic complete response (pCR) without a clear safety or surgical feasibility penalty in patients with microsatellite-stable (MSS) locally advanced rectal cancer,...
‘Save Research’ Campaign Champions Federal Funding
ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline. “The People Behind the Progress,” an ASCO social media series, features members sharing how federal cancer research has...
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) recently approved daraxonrasib, (Rasonque), a multiselective RAS(ON) inhibitor, for treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. ...
Structured Exercise After Adjuvant Chemotherapy for Colon Cancer Improves Survival and Saves Costs
A structured exercise program after adjuvant chemotherapy for colon cancer improved survival and saved money. In a preplanned cost-utility analysis of the phase III CHALLENGE trial, presented at the 2026 ASCO Annual Meeting1 and published simultaneously in the Journal of Clinical Oncology,2 the...
Long-Term Trial Supports Selective Use of Extended Pelvic Lymph Node Dissection in High-Grade Prostate Cancer
Extended pelvic lymph node dissection has long been used during radical prostatectomy to improve staging in men with higher-risk prostate cancer. Whether the more extensive operation also improves cancer outcomes has been less clear. New long-term randomized data presented at the 2026 American...
NSCLC: FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
ESMO Announces 2026 Society Award Recipients
The European Society for Medical Oncology (ESMO) has announced the recipients of the 2026 ESMO Society Awards, recognizing four outstanding oncology professionals whose contributions have advanced cancer research, enhanced clinical care, and strengthened the global oncology community. ESMO Award...
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
According to the results of a retrospective analysis reported by Jeong et al in JCO Precision Oncology, early molecular response assessed using circulating tumor DNA (ctDNA) was associated with radiographic response and longer time to progression among patients with recurrent high-grade serous...
SUO/AUA Updates Guidelines for Non–Muscle Invasive Bladder Cancer
The American Urologic Association (AUA), in partnership with the Society of Urologic Oncology (SUO) has released an amendment for 2026 to the Diagnosis and Treatment of Non–Muscle Invasive Bladder Cancer (NMIBC) Guideline, published in The Journal of Urology. The amendment introduces 40 new and...
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
A refined dynamic prognostic model incorporating longitudinal measurable residual disease (MRD) assessments may improve prediction of progression-free survival and overall survival in patients with chronic lymphocytic leukemia (CLL) receiving limited-duration therapy. The findings, reported by...
Robert A. Kyle, MD, Myeloma Expert, Dies at 98
The International Myeloma Foundation (IMF) shared news of the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Prostate Cancer: Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Patients with nonmetastatic prostate cancer who consumed higher quantities of saturated fats, including animal fats, had a higher risk of all-cause mortality, including death from cardiovascular disease and other cancer, according to the results of a study published in JAMA Network Open. “Our...
Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer
Long-course chemoradiotherapy resulted in superior 12-month total mesorectal excision–free survival compared with short-course radiotherapy in the STAR-TREC trial. The interim analysis, led by Simon P. Bach, FRCS, and colleagues and published in The Lancet Oncology, included patients pursuing organ ...
Duane A. Mitchell, MD, PhD, Named Director of the UF Health Cancer Institute
The University of Florida has selected Duane A. Mitchell, MD, PhD, as the next Director of the UF Health Cancer Institute. Dr. Mitchell, the Phyllis Kottler Friedman Professor in the Department of Neurosurgery, assumes the role September 21 at a pivotal moment for the institute, which earned...
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, HER2-negative...
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
In addition to searching for breast cancer, artificial intelligence (AI) used in mammography reads may help to detect common cardiovascular diseases, according to study findings presented at the ESC Congress 2026. “Because mammography is already widely used, analyzing the same images for...
Prostate Cancer: Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
A set of uncontrolled, modifiable cardiovascular risk factors may help identify a subgroup of patients with prostate cancer who could benefit from additional cardiovascular care, according to findings published in JACC: CardioOncology and presented at the ESC Congress 2026. “The major findings...
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Over the past 75 years, advances in the treatment of major blood cancers have saved more than 25 million years of life in the United States, according to results of an analysis led by researchers at Blood Cancer United and published by Chang et al in Blood Advances. But the gains have not reached...
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
Cervical cancer remains a preventable cause of morbidity and mortality, particularly among women who are not reached by screening programs. In a research letter published in JAMA Network Open, Sonawane et al emphasized the importance of identifying those who have never been screened and reported...
Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer
Secondary analyses of the prospective EA1181/CompassHER2 pCR trial identified clinicopathologic and molecular factors associated with pathologic complete response (pCR) after de-escalated neoadjuvant therapy with a taxane plus trastuzumab and pertuzumab (THP) in patients with stage II to IIIA...
